Skip to content Skip to Search
Skip navigation

Mubadala joins $680m acquisition of UCB’s Chinese business

By Pramod Kumar
The deal includes UCB’s neurology and allergy portfolios in mainland China and its Zhuhai manufacturing site UCB
The deal includes UCB’s neurology and allergy portfolios in mainland China and its Zhuhai manufacturing site

Abu Dhabi-based Mubadala Investment Company and Singapore’s CBC Group have jointly acquired the neurology and allergy business of UCB, a Belgian biopharmaceutical company, for $680 million.

The deal includes UCB’s neurology portfolio (Keppra, Vimpat and Neupro) and allergy portfolio (Zyrtec and Xyzal) in mainland China and its Zhuhai manufacturing site.

The combined net sales for these medicines in China reached €131 million ($146.5 million) in 2023. 

Person, Electronics, Mobile Phone

Newsletter
Get the Best of AGBI delivered straight to your inbox every week

Mubadala will support the next phase of the development of UCB’s platform as it delivers transformative medicines to the markets, said Mohamed Albadr, head of China.  

The transaction is subject to closing conditions, including required anti-trust clearances. It is expected to close in the fourth quarter of 2024.  

PJT Partners is the financial advisor to CBC Group and Mubadala, while Clifford Chance is the legal advisor.

Mubadala Capital, the asset management subsidiary of sovereign fund Mubadala Investment, has focused on biotechology investments of late. It participated in early-stage investments into Seattle cell therapy specialists Outpace Bio, New York’s Metsera and California’s Capstan Therapeutics, data from PitchBook shows.

Combined, these deals – which include other investors – were worth $617 million, PitchBook estimates.

Biotechnology uses living organisms to make products, often pharmaceuticals. There are nearly 7,600 biotech-based drugs in development in the US according to the Biotechnology Innovation Organization.

Latest articles

Saudi hotel llicences. Hajj pilgrims from Indonesia at a hotel in Mecca. Pilgrimages form a large part of Saudi Arabia's tourism goals

Saudi Arabia scraps hotel licence fees to draw investment

Saudi Arabia has removed licensing fees for hotels and resorts in a further effort to increase tourism and improve the kingdom’s investment environment.  The Ministry of Tourism and Ministry of Municipalities and Housing said they would ask hotel establishments to reapply for operating licences online. The decision applies to hotels, hotel apartments and residential resorts.  […]

Mubadala Getir New York

Mubadala applies to take full control of Turkey’s Getir

The Abu Dhabi sovereign wealth fund Mubadala has formally applied to take full control of the Turkish grocery delivery startup Getir. Mubadala had taken a majority controlling stake in the company in June this year as part of a restructuring programme, with a capital injection of $250 million. The filing to take over Getir was […]

PIF spending Yasir Al-Rumayyan

PIF spending to hit $70bn a year early, says IMF

Saudi Arabia’s Public Investment Fund will raise its annual spending to $70 billion in 2025, a year earlier than previously announced, according to an International Monetary Fund official.  PIF’s governor Yasir Al-Rumayyan told a Saudi investment summit in February that the sovereign wealth fund would increase its annual capital spending from around $50 billion a […]

Opec secretary general Haitham Al Ghais. Analysts say the body is running out of options to stabilise oil prices

Opec+ delay to output rise fails to rejuvenate oil price

The decision by Opec+ on Thursday to postpone its oil output hike until December has failed to pump up the markets, where the sentiment remains bearish.  While Opec+ still holds sway over global balances, it is running out of options to stabilise prices, analysts said, as the share price of Aramco, the world’s biggest producer, […]